FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Peterson Caryn 2. Issuer Name and Ticker or Trading Symbol Gossamer Bio, Inc. [ GOSS ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, Regulatory Affairs
(Last)          (First)          (Middle)
3013 SCIENCE PARK ROAD		 3. Date of Earliest Transaction (MM/DD/YYYY)
5/5/2023
(Street)
SAN DIEGO, CA 92121		 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)        (State)        (Zip)
 Rule 10b5-1(c) Transaction Indication
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $22.1  5/5/2023    D        48500    (1) 3/25/2029  Common Stock  48500.0   (2) 0  D   
Stock Option (Right to Buy)  $16.4  5/5/2023    D        13750    (3) 12/23/2029  Common Stock  13750.0   (4) 0  D   
Stock Option (Right to Buy)  $14.55  5/5/2023    D        34175    (5) 2/14/2030  Common Stock  34175.0   (6) 0  D   
Stock Option (Right to Buy)  $9.79  5/5/2023    D        28250    (7) 2/25/2031  Common Stock  28250.0   (8) 0  D   
Stock Option (Right to Buy)  $8.49  5/5/2023    D        31750    (9) 4/16/2031  Common Stock  31750.0   (10) 0  D   
Stock Option (Right to Buy)  $11.94  5/5/2023    D        190000    (11) 1/5/2032  Common Stock  190000.0   (12) 0  D   
Stock Option (Right to Buy)  $1.36 (13) 5/5/2023    A     32334       (1) 3/25/2029  Common Stock  32334.0   (2) 32334  D   
Stock Option (Right to Buy)  $1.36 (13) 5/5/2023    A     9167       (3) 12/23/2029  Common Stock  9167.0   (4) 9167  D   
Stock Option (Right to Buy)  $1.36 (13) 5/5/2023    A     22784       (5) 2/14/2030  Common Stock  22784.0   (6) 22784  D   
Stock Option (Right to Buy)  $1.36 (13) 5/5/2023    A     18834       (7) 2/25/2031  Common Stock  18834.0   (8) 18834  D   
Stock Option (Right to Buy)  $1.36 (13) 5/5/2023    A     21167       (9) 4/16/2031  Common Stock  21167.0   (10) 21167  D   
Stock Option (Right to Buy)  $1.36 (13) 5/5/2023    A     126667       (11) 1/5/2032  Common Stock  126667.0   (12) 126667  D   

Explanation of Responses:
(1)  The shares subject to the option are fully vested.
(2)  On May 5, 2023, the Issuer canceled an option granted on March 25, 2019. In exchange for the canceled option, the reporting person received 32,334 options to purchase common stock having a lower exercise price with the same vesting terms.
(3)  25% of the total number of shares subject to the option vested on December 23, 2020 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
(4)  On May 5, 2023, the Issuer canceled an option granted on December 23, 2019. In exchange for the canceled option, the reporting person received 9,167 options to purchase common stock having a lower exercise price with the same vesting terms.
(5)  25% of the total number of shares subject to the option vested on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
(6)  On May 5, 2023, the Issuer canceled an option granted on February 14, 2020. In exchange for the canceled option, the reporting person received 22,784 options to purchase common stock having a lower exercise price with the same vesting terms.
(7)  25% of the total number of shares subject to the option vested on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
(8)  On May 5, 2023, the Issuer canceled an option granted on February 25, 2021. In exchange for the canceled option, the reporting person received 18,834 options to purchase common stock having a lower exercise price with the same vesting terms.
(9)  25% of the total number of shares subject to the option vested on April 16, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
(10)  On May 5, 2023, the Issuer canceled an option granted on April 16, 2021. In exchange for the canceled option, the reporting person received 21,167 options to purchase common stock having a lower exercise price with the same vesting terms.
(11)  One-third of the total number of shares subject to the option vested on January 6, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
(12)  On May 5, 2023, the Issuer canceled an option granted on January 6, 2022. In exchange for the canceled option, the reporting person received 126,667 options to purchase common stock having a lower exercise price with the same vesting terms.
(13)  The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Peterson Caryn
3013 SCIENCE PARK ROAD
SAN DIEGO, CA 92121

EVP, Regulatory Affairs

Signatures
/s/ Jeff Boerneke, Attorney-in-Fact 5/9/2023
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Aug 2023 to Sep 2023 Click Here for more Gossamer Bio Charts.
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Sep 2022 to Sep 2023 Click Here for more Gossamer Bio Charts.